Pump, pipes, and filter: do SGLT2 inhibitors cover it all?

Affiliations

¹ Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Toronto M5B 1W8, ON, Canada; Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, ON, Canada. Electronic address: vermasu@smh.ca.
² Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, ON, Canada.

Comment

Subodh Verma et al. Lancet. 2019.

. 2019 Jan 5;393(10166):3-5.

doi: 10.1016/S0140-6736(18)32824-1. Epub 2018 Nov 10.

¹ Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Toronto M5B 1W8, ON, Canada; Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, ON, Canada. Electronic address: vermasu@smh.ca.
² Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, ON, Canada.

No abstract available

Comment on

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. Zelniker TA, et al. Lancet. 2019 Jan 5;393(10166):31-39. doi: 10.1016/S0140-6736(18)32590-X. Epub 2018 Nov 10. Lancet. 2019. PMID: 30424892